New Blood Test Could Detect Alzheimer’s Early And Reveal Disease Stage, Scientists Say

Scientists

may be one step closer to transforming how Alzheimer’s disease is diagnosed with the development of a simple blood test that can detect the condition early and reveal how far it has progressed. The new test could provide a cheaper, faster, and less invasive alternative to current diagnostic methods such as PET brain scans and spinal taps, which are expensive and often difficult for many patients to access. Researchers say the blood-based model may help doctors identify Alzheimer’s disease earlier, improving treatment decisions and potentially slowing disease progression.

How the blood test works?

The test focuses on measuring two forms of tau protein in the blood. Tau proteins are strongly associated with Alzheimer’s disease because abnormal accumulations can damage brain cells and interfere with memory, thinking, and behavior. Researchers tested the model on more than 1,000 participants, including:

• Cognitively healthy individuals
• Patients with mild cognitive impairment
• People diagnosed with Alzheimer’s dementia
• Patients with other neurodegenerative disorders

The findings showed that the blood test was highly accurate in staging Alzheimer’s disease. Results from the blood model closely matched PET brain scans, which are currently among the most reliable tools used to detect Alzheimer ’s-related brain changes.

Why experts say this could be a major breakthrough?

Medical experts believe the blood test could significantly improve access to Alzheimer’s screening worldwide. Dr. Randy D’Amico, director of the Brain and Spine Metastasis Program of Neurosurgery at Northwell Lenox Hill Hospital in New York City, reviewed the findings but was not involved in the study. “If the data hold up in bigger studies, I think it can really dramatically expand access to biological Alzheimer’s testing, which is a big deal,” he said. Experts say easier testing could encourage more people to seek medical evaluation for early memory problems without fear of undergoing invasive procedures.

Earlier detection could improve treatment

Doctors say the ability to “stage” Alzheimer’s disease through a blood test may help physicians tailor treatments more effectively, similar to how cancer staging guides therapy decisions. Early diagnosis is considered critical because much of the brain damage caused by Alzheimer’s becomes irreversible over time. Detecting the disease before symptoms become severe could allow patients to benefit from newer therapies, cognitive support programs, and lifestyle changes earlier in the disease process. Researchers believe better staging could also help doctors identify which patients may respond best to emerging Alzheimer’s medications.

Alzheimer’s cases rising worldwide

Alzheimer’s disease is the most common cause of dementia globally and affects millions of older adults. Symptoms often include:

• Memory loss
• Confusion
• Difficulty communicating
• Mood and personality changes
• Trouble with reasoning and daily activities

As populations age, experts warn that the global burden of Alzheimer’s disease is expected to increase significantly in the coming decades.

More research still needed

While the results are encouraging, scientists caution that larger studies are still needed before the blood test becomes widely available in hospitals and clinics. Future research will need to confirm how accurately the test performs across diverse populations and in real-world healthcare settings. Still, researchers say the findings represent an important step toward simpler and more accessible Alzheimer’s diagnosis - raising hopes that one day the disease could be detected earlier and managed more effectively with a routine blood test.